Related Experiment Videos
EEG recordings following intrathecal iohexol administration
V E Drory1, E Avrahami, M Y Neufeld
1Department of Neurology, Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Clinical Neuropharmacology
|August 1, 1990
Summary
Iohexal (Omnipaque) demonstrated safety in patients undergoing spinal imaging. Electroencephalogram (EEG) monitoring revealed no adverse neurological effects after intrathecal administration, suggesting it is a safer contrast agent.
Area of Science:
- Neuroradiology
- Neurophysiology
- Pharmacology
Background:
- Intrathecal contrast agents are used in neuroimaging.
- Previous contrast media, like metrizamide, have shown encephalopathic effects.
- Evaluating the safety of newer contrast agents is crucial.
Purpose of the Study:
- To assess the encephalopathic potential of iohexal (Omnipaque) after intrathecal administration.
- To compare the safety profile of iohexal with other commonly used contrast agents.
Main Methods:
- Electroencephalogram (EEG) recordings were obtained from 30 patients.
- Recordings were taken before, several hours after, and 24 hours after intrathecal iohexal administration.
- Procedures included cervical myelography and cisternography.
Main Results:
- No EEG abnormalities were detected in any patient post-administration.
- Iohexal did not induce significant neurological changes detectable by EEG.
- The contrast medium was well-tolerated.
Conclusions:
- Iohexal is a safe intrathecal contrast medium.
- Iohexal exhibits fewer encephalopathic effects compared to metrizamide.
- This suggests iohexal is a favorable alternative for spinal imaging procedures.